Edition:
United Kingdom

Genetic Technologies Ltd (GENE.OQ)

GENE.OQ on NASDAQ Stock Exchange Capital Market

1.25USD
23 May 2018
Change (% chg)

$0.03 (+2.46%)
Prev Close
$1.22
Open
$1.25
Day's High
$1.25
Day's Low
$1.23
Volume
1,634
Avg. Vol
29,842
52-wk High
$2.05
52-wk Low
$0.70

Chart for

About

Genetic Technologies Limited is a molecular diagnostics company. The Company is engaged in the provision of molecular risk assessment for cancer. The Company offers predictive testing and assessment tools for physicians to manage women's health. The Company's lead product, BREVAGenplus, is a clinically validated risk assessment... (more)
No analyst recommendations are available for .

Overall

Beta: 2.64
Market Cap(Mil.): $15.14
Shares Outstanding(Mil.): 16.24
Dividend: --
Yield (%): --

Financials

  GENE.OQ Industry Sector
P/E (TTM): -- 84.06 32.75
EPS (TTM): -0.47 -- --
ROI: -74.37 1.57 14.38
ROE: -74.83 2.43 16.07

BRIEF-Genetic Technologies Enters Into A Non-Binding Terms Sheet With Omix Ventures Private ​

* ENTERED INTO A NON-BINDING TERMS SHEET WITH OMIX VENTURES PRIVATE ​

06 Mar 2018

BRIEF-Genetic Technologies Says H1 Comprehensive Loss Attributable $3.3 Mln

* H1 REVENUE FROM CONTINUING OPERATIONS - GENETIC TESTING SERVICES $97.8 MILLION VERSUS $369.1 MILLION

26 Feb 2018

BRIEF-Genetic Technologies ‍Enters Terms Sheet With Blockchain Global​

* ‍ENTERED INTO NON-BINDING TERMS SHEET WITH BLOCKCHAIN GLOBAL​

15 Feb 2018

BRIEF-Genetic Technologies Says Eutillio​ ‍Buccilli To Step Down As CEO

* EUTILLIO​ ‍BUCCILLI WILL STEP DOWN AS CHIEF EXECUTIVE OFFICER WITH IMMEDIATE EFFECT

06 Feb 2018

BRIEF-Genetic Technologies Appointed Paul A. Kasian As Chairman

* MALCOLM. R BRANDON RESIGNS AS CHAIRMAN Source text for Eikon: Further company coverage:

05 Feb 2018

BRIEF-Genetic Technologies Seeks Trading Halt

* SEEKS TRADING HALT ‍PENDING AN ANNOUNCEMENT ON OUTCOME OF RESULTS OF GENERAL MEETING OF SHAREHOLDERS SCHEDULED​ Source text for Eikon: Further company coverage:

30 Jan 2018

BRIEF-Genetic Technologies Provides Update On Strategic Review Initiative

* GENETIC TECHNOLOGIES PROVIDES UPDATE ON STRATEGIC REVIEW INITIATIVE

12 Dec 2017

Competitors

Earnings vs. Estimates